Skip to content
Search

Latest Stories

RPS calls for measures to protect pharmacy teams against Omicron

The Royal Pharmaceutical Society (RPS) has called for adoption of protection and control measures to safeguard pharmacy teams against Omicron.

This follows an updated guidance on infection protection and control issued by the UK Health Security Agency, which reinforces the actions needed to prevent transmission of Covid-19 and other respiratory viruses.


RPS president professor Claire Anderson said: “As our understanding of the Covid-19 pandemic evolves and new evidence emerges, we must keep pace with infection control risk assessments to keep staff as safe as possible in the pharmacy.

“As Omicron is so transmissible, it’s vital that measures are in place to protect staff health and help minimise staff absences, which have such an impact on workplace pressure and patient care."

She noted that health and care staff have worked hard to provide patient care over the past 21 months, and now employers and the NHS must ensure that “pharmacy teams receive the support and protection they deserve in the workplace.”

“This includes adapting to individual needs, as well as making sure that broader rules around social distancing, ventilation and use of appropriate PPE are all in place and being observed.”

She added that PCR and LFT testing should be prioritised for all those working across health care services.

"Both employers and employees have a duty of care and responsibility to protect each other, we hope that by revisiting risk assessments and infection control measures action will be taken to ensure staff are protected.”

RPS has also issued a guidance that includes latest information about risk assessments, PPE and social distancing to help protect pharmacy teams.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less